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Background: Temporary hypocalcemia is a frequent complication after total thyroidectomy. Routine post-
operative administration of vitamin D and calcium can reduce the incidence of symptomatic postoperative
hypocalcemia. We undertook a systematic review to assess the effectiveness of this intervention.
Methods: We identiﬁed randomized controlled trials comparing the administration of vitamin D or
metabolites to oral calcium or no treatment in patients after total thyroidectomy in MEDLINE, EMBASE
and LILACS databases.
Results: Four studies with 706 patients were included: 346 in the calcitriol group, 288 in the oral calcium
group and 72 in the control group. The rates of hypocalcemia symptomswere 4%,19% and 31%, respectively.
TheOR value for the comparison between calcitriolþ calciumas compared tono treatment and to exclusive
calcium treatment groups was 0.32 (95% CI, 0.13e0.79) and 0.31 (95% CI, 0.14e0.70), respectively.
Conclusion: The prophylactic treatment with vitamin D or metabolites þ calcium is effective to decrease
the incidence of symptoms of temporary hypocalcemia.
 2010 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.1. Introduction
Thyroidectomy is the most common surgical procedure per-
formed in the neck by surgeons. Hypocalcemia is the most frequent
complication after total thyroidectomy, and it is the main cause of
prolonged hospital stay.1e3 Hypocalcemia can occur from the
immediate postoperative period up to ﬁve days after surgery, and it
is described as one of the most unpleasant experiences because of
symptoms of tingling, spasm and chest oppression in severe cases.
The rate of symptomatic postoperative hypocalcemia ranges from 5
to 50%,4 but only 1e3% of cases is deﬁnitive. Treatment of post-
operative hypocalcemia depends on its severity. For mild cases, oral
vitamin D and calcium supplements are enough to relieve symp-
toms and return serum calcium values to normal levels. In cases of
severe hypocalcemia, emergency admission to the hospital is
necessary, which involves periodic serum calcium measurements,
administration of intravenous calcium gluconate and supplemen-
tation with high doses of oral vitamin D and calcium.
Based on the extent of tissue involved, thyroidectomy could be
classiﬁed as an intermediate procedure, necessitating an outpatientr. Toronto, Canada. August 9,
abria).
ciates Ltd. Published by Elsevier Ltprocedure in the majority of cases.5,6 However, symptoms of hypo-
calcemia limit theuseof thyroidectomyasanoutpatientproceduredue
to the high frequency of symptoms, general unpleasantness of them,
and the risk of severe consequences such as cardiorespiratory arrest.
To address these issues, some authors have suggested that
routine measurements of serum calcium and parathyroid hormone
could predict the development of hypocalcemia, allowing doctors to
treat patients before symptoms appear.7 However, this strategy has
not been successful because symptomatic hypocalcemia is a multi-
factorial condition. Others have suggested the routine prophylactic
administration of oral vitamin D and calcium in the postoperative
period to reduce the rate of symptomatic hypocalcemia.8e12
However, the number of studies and patients included in indi-
vidual studies are lowand do not offer clear evidence of the beneﬁts
of this therapy. In this case, a meta-analysis could offer a more
precise evaluation of the effectiveness of treatment.
The aim of this study was assess the effectiveness of prophy-
lactic administration of vitamin D or metabolites and calcium in
patients who underwent total thyroidectomy.
2. Materials and methods
We performed a bibliography search on the MEDLINE, EMBASE and LILACS
databases for studies published from January 1980 to April 2008 using theMESH and
free terms “thyroidectomy”, “thyroid surgery”, “calcitriol” and “vitamin D”. An
expanded search was used using Boolean operators. References were explored tod. All rights reserved.
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were reviewed, and those which dealt with the use of vitamin D or metabolites after
thyroidectomy as a therapy to avoid postoperative hypocalcemia were selected for
further analysis. We assumed bioequivalence of vitamin D (cholecalciferol) and its
direct metabolite, calcitriol, because the ﬁrst is the precursor of the second, have the
samepharmacological properties and offer a similarmechanismof action and clinical
effect. Criteria for inclusion of studies were as follows: randomized controlled trial
(RCT) comparing the administrationof oral vitaminDormetabolites associated ornot
with oral calcium or other medication to nothing, placebo or oral calcium adminis-
tration in patients submitted for total thyroidectomy with or without central neck
dissection for any cause, with postoperative clinical evaluation of hypocalcemia
symptoms and postoperative evaluation of blood calcium. Patients with a history of
neck surgery or radiotherapy or extensive surgical procedures and those operated on
due to concurrent parathyroid disease were excluded. Patients undergoing lateral
neck dissection were not excluded, assuming that hypoparathyroidism is not more
common when lateral neck dissections are performed simultaneously with total
thyroidectomy.13 The main outcomes assessed were clinical symptoms of hypocal-
cemia, deﬁned as circumoral tingling and Chvostek and Trousseau signs based on the
principles of outcomes research, where patient-centered outcomes offer more rele-
vant evidence for physicians who have to take clinical decisions.
Two independent investigators acquired data about the risk of bias (generation of
the allocation sequence, allocation concealment, blinding and follow up) according to
the recommendations of the Cochrane Collaboration.14We also recorded the inclusion
and exclusion criteria in each trial. The following details were extracted: (1) details of
the administration of vitamin D ormetaboliteswith orwithout othermedications; (2)
number and characteristics of randomized patients; (3) number of patients not
randomized and reasons; (4) exclusion after randomization; (5) drop-outs; and (6)
‘intention-to-treat’ analysis. Authors were contacted in cases of missing data. Data-
related conﬂicts were solved by consensus. The statistical package Stata 8.0 (Stata
Corporation, TX, USA) was used. For dichotomous outcomes, the impact of the inter-
ventionwas expressed as anodds ratiowith95% conﬁdence intervals. In theanalysis of
continuous variables, we employed means with standard deviations. We used
a random-effectsmodel. The chi-squared test forheterogeneitywasused toprovidean
indication of between-study heterogeneity. Furthermore, we explored the causes of
heterogeneity using a meta-regression. We used a funnel plot to provide a visual
assessment andused theadjusted rank correlation test (Begg test) to assess funnelplot
asymmetry. The number needed to treat was calculated using Cates method.3. Results
The primary search with the selected terms identiﬁed 776
articles. From this sample, 12 studies were identiﬁed as candidates,but only four of these studies satisﬁed the inclusion criteria.4,9,10,15
The reasons for excluding the other studies were a non-randomized
design8,12,16e20 and a preoperative intervention with no post-
operative hypocalcemia data.11 (Fig. 1) Study characteristics and
quality evaluation are shown in Tables 1 and 2. The kappa-weighted
coefﬁcient was 0.76.
Regarding methodological quality, any study used placebo.
Bellantone9 and Roh10 studies offered no treatment as control
group and Tartaglia15 and Pisaniello4 offered calcium without
Vitamin D or metabolites as control group. Blinding evaluation was
satisfactory only in Pisaniello trial4 and unclear in the others.
Authors were contacted to clear this data, but only Roh10 and Tar-
taglia15 answered the requests. The lack of a placebo arm and
weakness of blinding are important factors that could bias the
results in favor of treatment.
A study byBellantone9 showednodifference in serumcalciumor
parathyroid hormone levels at day 7. Furthermore, patients treated
with vitamin D or metabolites and oral calcium developed milder
symptoms of hypocalcemia in comparison with patients in the
control group. Therapy with vitamin D or metabolites and calcium
was suspended in 85% of patients at postoperative day 7 and in 97%
at postoperative day 30. Pisaniello4 reported differences in serum
calcium levels at postoperative days 1, 2 and 3; calcium levels were
higher in the group treated with vitamin D or metabolites. There is
no information available regarding the time when treatment was
suspended. The only adverse event reported in patients who
received vitamin D or metabolites was gastric pyrosis. There is no
information about the rate of permanent hypoparathyroidism. Tar-
taglia15 showed differences in serum calcium, only on the ﬁrst
postoperative day. They reported that treatment for all patients was
suspended at day 15 postoperatively, with a progressive decrease of
doses (0.5 mg of calcitriol and 125mg of calcium every 3e5 days). At
six months postoperatively, 3% of patients in the 0.5 mg calcitriol
group, 2% of patients in the 1 mg calcitriol group and 4% of patients in
the control group had permanent hypoparathyroidism. There was
no difference when the outcome analyzed was the frequency of
Table 1
Included study descriptions.
Bellantone Roh Pisaniello Tartaglia
COUNTRY Italy Korea Italy Italy
PATIENTS Total thyroidectomy, excluding:
1. previous thyroid or neck operation
or irradiation,
2. substernal goiter,
3. Concomitant central or lateral
neck dissection,
4. Concomitant parathyroid disease,
5. Video-assisted thyroidectomy
Malignancy rate 22%;
Hyperthyroidism rate 8%
Total thyroidectomy, excluding:
1. previous thyroid or neck operation
or irradiation,
2. Abnormal renal function
Malignancy rate 83%;
Hyperthyroidism rate 5%
Total thyroidectomy, excluding:
1. hypercalcemia;
2. chronic renal failure.
Malignancy rate 8.5%
Hyperthyroidism rate not reported
Total thyroidectomy, excluding:
1. previous surgery;
2. concomitant lymph dissection;
3. hyperparathyroidism.
Malignancy rate 20.6%;
Hyperthyroidism rate 13.1%
INTERVENTION Two groups: 1. oral calcium carbonate 1 g
every 8 hours and rescue therapy for
symptomatic patients with calcitriol 0.5 mg
every 12 hours; 2. oral calcium carbonate 1 g
every 8 hours plus calcitriol 0.5 mg every 12 hours.
Intraoperative parathyroid gland
management not stated.
oral calcium carbonate 1 g every
8 hours plus vitamin D 0.5 g every
12 hours until postoperative day 14.
Intraoperative parathyroid gland
management: carefully preservation
and transplantation.
oral calcium carbonate 1500 mg
per day, vitamin D 400 IU per day.
All patients receive thyroid hormone
on postoperative day 1.
Intraoperative parathyroid gland
management not stated.
Two groups: 1. Oral calcium
carbonate 500 mg every
8 hours þ calcitriol 0.5 mg
twice per day; 2. Oral calcium
carbonate 500 mg every
8 hours þ calcitriol 1 mg twice per day.
Intraoperative parathyroid
gland management: carefully
preservation a. No transplantation
CONTROL No treatment, rescue therapy for
symptomatic patients with oral calcium 1 g
every 8 hours plus calcitriol 0.5 mg every 12 hours
No treatment, rescue therapy for
symptomatic patients with oral
calcium 1 g every 8 hours plus
vitamin D 0.5 g every 12 hours
Oral calcium carbonate 3000 mg per day,
rescue therapy for symptomatic patients
with intravenous calcium. All patients receive
thyroid hormone on postoperative day 1.
1. Oral calcium carbonate 1500 mg per day
OUTCOME Serum calcium and parathyroid hormone levels
in postoperative day 1, 2, 3, 7. Hypocalcemia
deﬁned as serum calcium <8.0 mg/dl
Clinical assessment of hypocalcemia “signs of
hypocalcemia and evaluation of Chvostek’s sign”
Serum calcium and parathyroid
hormone levels on postoperative day
1, 2, 3, 7. Hypocalcemia deﬁned as ionized
calcium <1.0 mmol/L and serum
calcium <8.0 mg/dl
Clinical assessment of hypocalcemia
“perioral tingling and numbness
to carpopedal
spasms and tetany”
Serum calcium levels on postoperative day
1, 2, 3, 30, 60, 90, 120. Hypocalcemia
deﬁned as serum calcium <8.0 mg/dl
Clinical assessment of hypocalcemia
“perioral tingling, muscle cramp,
Chvostek’s and Trousseau’s signs”
Serum calcium levels on
postoperative day 1, 2, 3, 30,
60, 90, 120. Hypocalcemia
deﬁned as serum calcium <8.0 mg/dl
Clinical assessment of hypocalcemia
“paresthesias and tetany;
.as spontaneous
masseter muscle contraction
and carpal spasm.presence
of serious and widespread
paresthesias with
positive Trousseau’s sign.”
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Table 2
Risk of bias evaluation.
Bellantone Pisaniello Tartaglia Roh
Sequence generation Yes Yes No Yes
Allocation concealment UNCLEAR UNCLEAR UNCLEAR UNCLEAR
Blind evaluation UNCLEAR Yes UNCLEAR UNCLEAR
Incomplete outcome data No No No No
Intention-to-treat analyses Yes Yes Yes Yes
Statistical methods description Yes Yes Yes Yes
Intervention criteria description Yes Yes Yes Yes
Odds ratio
.1 1 10
Study
 % Weight
 Odds ratio
 (95% CI)
 0.44 (0.13,1.44) Bellantone  56.3
 0.22 (0.06,0.86) Roh  43.7
 0.32 (0.13,0.79) Overall (95% CI)
Fig. 2. Forrest plot for comparison between vitamin D or metabolites þ calcium vs. no
treatment.
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serum calcium but not in parathyroid hormone on postoperative
days 1, 2 and 7. Patients treated with vitamin D or metabolites and
oral calcium developed milder symptoms of hypocalcemia in
comparison with patients in the control group. There is no infor-
mation about the rate of permanent hypoparathyroidism.
The RCTs selected included 706 patients: 346 in the vitamin D or
metabolites group, 288 in the oral calcium group and 72 in the
control group (Table 3). The rate of hypocalcemia symptoms was
13/346 (4%, 1e23%) patients in the vitamin D or metabolites group,
28/288 (19%, 7e35%) in the oral calcium group and 22/72 (31%,
24e41%) in the control group. The OR value for the comparison
between calcitriolþ calcium as compared to no treatment was 0.32
(95% CI, 0.13e0.79). Statistical heterogeneity was not identiﬁed
(P ¼ 0.45) (Fig. 2). The number needed to treat was six (95% CI,
4e12). The OR value was 0.31 (95% CI, 0.14e0.70) for the compar-
ison between the vitamin D or metabolites and exclusive calcium
treatment groups. Statistical heterogeneity was not identiﬁed
(P ¼ 0.40) (Fig. 3). The number needed to treat was six (95% CI,
4e19). The funnel plot for the comparison between vitamin D or
metabolites and oral calcium did not show asymmetry. The Begg
test showed a P-value of 0.56.
As malignancy and hyperthyroidism rates could be a source of
heterogeneity between studies, we used these variables to make
a meta-regression. A meta-regression is a statistical method which
assesses the effect of a covariable on the ﬁnal result of the meta-
analysis. The results of this regression did not show a statistically
signiﬁcant difference (p > 0.05), but its statistical power is low in
reviews with few trials. For the case of intraoperative management
of parathyroid glands, the heterogeneity of the data did not allow
any adjustment.4. Discussion
Postoperative hypocalcemia is a common problem after
thyroidectomy, due to its high frequency and the decrease in
quality of life for patients who suffer from severe symptoms.1,2
Furthermore, postoperative hypocalcemia has increased the
length of stay and discouraged the widespread use of thyroidec-
tomy as an outpatient procedure.3,5,6Table 3
Patients and outcomes data.
AUTHOR VITAMIN D
GROUP
Hypocalcemia
symptoms (%)
ORAL CALCIUM
GROUP
Hypocalcem
symptoms (%
Roh 45 3 (6.6)
Bellantone 26 6 (23.0) 26 9 (34.6)
Pisaniello 60 1 (1.6) 60 4 (6.6)
Tartaglia 104a 3 (2.8) 202 15 (7.4)
111b 0 (0)
215 3 (1.4)
a Vitamin D group 0.5 mg.
b Vitamin D group 1 mg.Some authors have tried to assess the utility of serum calcium
and parathyroid hormone measurements in the postoperative
periodas away topredictwhichpatientswill develophypocalcemia.
Selecting the most recent articles published on MEDLINE was
expected to elucidate the efﬁcacy of this approach. Toniato et al.7
assessed pre- and postoperative measurement of PTH and found
a speciﬁcity and positive predictive value of 96% and 93%, respec-
tively. However, sensitivity was low. Cavicchi et al.21 found a sensi-
tivity of 100% with a speciﬁcity ranging from 46 to 85%. Erbil et al.22
found a 16-fold increase in the risk of hypocalcemiawith PTH levels
under 10 pg/ml. If we assume a speciﬁcity of 95% similar to the other
studies, the expected sensitivity is approximately 80%. These results
show that even in the best hands andwith the availability ofmodern
serumtests, it is noteasy topredictwith certaintywhichpatients are
going to develop postoperative hypocalcemia.
Other authors suggested the use of routine prophylactic vitamin
D or metabolites þ calcium or exclusive calcium as an alternative
strategy to decrease the rate of hypocalcemia, based on the prin-
ciple that offering prophylaxis to all patients will help all suscep-
tible patients, even those that are not detected by serum tests. This
approach would avoid the routine measurement of serum calcium
and in cases of symptomatic hypocalcemia; the crisis will be less
severe and easy to treat in comparison with patients who do not
receive any prophylaxis.8e12 On the other hand, based on the
philosophy of patient-centered outcomes, levels of calcium or PTH
do not necessarily represent the most important ﬁnal clinical
outcome for the patients: the symptoms of hypocalcemia. Only four
studies assessed the effectiveness of this therapy under the
demanding conditions of an RCT. However, although individually
the trials showed a statistically signiﬁcant difference, the sample
size of each one was too small to allow reliable conclusions and
does not offer a precise estimate. Ourmeta-analysis withmore than
700 patients showed a decrease of almost 70% in the rate ofia
)
NO INTERVENTION
GROUP
Hypocalcemia
symptoms (%)
PATIENTS
TOTAL
Hypocalcemia
TOTAL (%)
45 11 (24.4) 90 14 (15.5)
27 11 (40.7) 79 26 (36.7)
120 5 (4.2)
417 94 (22.5)
Odds ratio
.1 1 10
Study
 % Weight
 Odds ratio
 (95% CI)
 0.18 (0.05,0.62) Tartaglia  42.0
 0.24 (0.03,2.19) Pisaniello  13.4
 0.57 (0.17,1.92) Bellantone  44.6
 0.31 (0.14,0.70) Overall (95% CI)
Fig. 3. Forrest plot for comparison between vitamin D or metabolites þ calcium vs.
exclusive calcium.
A. Sanabria et al. / International Journal of Surgery 9 (2011) 46e5150symptomatic postoperative hypocalcemia between the group
treated with vitamin D or metabolitesþ calcium as compared to no
prophylaxis or exclusive calcium groups. These results showed that
vitamin D or metabolites þ calcium is the most effective strategy.
However, the conﬁdence intervals are too wide to consider the
results obtained to be precise estimates.
The studies showed a signiﬁcant range of variability in patients’
characteristics. The rate of hyperthyroidism varied from 0 to 13%. In
the Tartaglia study15 where the rate of hyperthyroidismwas higher,
the OR of the individual study was lower, which supports the idea
that in cases of high risk, a larger protective effect is expected. Also,
themalignancy rate varied from8 to83%and the samephenomenon
occurs for the case of Roh study10 where the malignancy rate was
higher. The same argument could be used to support the inclusion of
patients with radical neck dissection as occurred in the Roh study10
(19%). Recent data from an RCT made by Roh in patients who
underwent total thyroidectomy and central neck dissection
conﬁrmed these assumptions.23 Even more, the randomized design
of the studies compensates for different types of surgery (as neck
dissection and methods to identify or manage the parathyroid
glands) and variations in the deﬁnitions of hypocalcemia. The main
principle of randomization is balancing between groups, known and
unknownvariables that could affect the ﬁnal outcome. As the rate of
permanent hypoparathyroidism was similar between studies it is
not expected that variability in the intraoperative management of
the parathyroid glands could have an important effect on the results
of the study. However, some elements related to methodological
quality such as the blind evaluation of results and allocation
concealment areweak in this analysis. This diminished the quality of
the trials, but this may be an effect of inadequate reporting because
the trials did not include all of the elements suggested by the
CONSORT statement.24 It is important to note that a lack of blind
evaluation and adequate allocation concealment may have biased
the results of these studies. One factor to consider is the method of
clinical detection of symptoms and the deﬁnition of clinically rele-
vant hypocalcemia. Up to date, only one instrument has been
speciﬁcally designed and statistically validated to assess the symp-
toms of postoperative hypoparathyroidism, but this scale is not
widely applied in trials assessing complications of thyroidectomy.25
Therefore, the detection of the symptom could be biased. However,
we consider that a careful collection of data in a previously designed
format could compensate the risk of bias derived from this lack of
homogeneity in the deﬁnition of hypocalcemia.
One probable advantage not included in this analysis is the
avoidance of routine serum calcium measurements. If theprophylaxis is administered, symptoms of hypocalcemia are the
markers of an adequate level of serum calcium. Furthermore, some
patients present low serum calcium levels but never suffer symp-
toms, which could potentially lead to the administration of calcium
or to extended hospital stays unnecessarily. Another advantage is
the ability to offer thyroidectomy as an outpatient procedure,
because the risk of hypocalcemia decreases to very low levels that
allow more conﬁdent ambulatory control.
Although some concerns exist about the possibility of developing
a temporary state of hypercalcemia, thesedata couldnotbeobtained
from the primary trials. Furthermore, the potential adverse vents
derived from the treatment in all patients, such as gastric symptoms
or constipation, were not adequately assessed in the studies and
could represent an increase in costs not considered in the analysis.
In conclusion, the use of prophylaxis for hypocalcemia
comprising vitamin D ormetabolitesþ calcium or exclusive calcium
is effective to decrease the incidence of symptoms of temporary
hypocalcemia.
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